Financial hardship among rural cancer survivors: An analysis of the Medical Expenditure Panel Survey.
Adult
Aged
Aged, 80 and over
Cancer Survivors
/ statistics & numerical data
Cost of Illness
Female
Financing, Personal
/ statistics & numerical data
Health Expenditures
/ statistics & numerical data
Humans
Insurance, Health
/ statistics & numerical data
Male
Middle Aged
Rural Population
/ statistics & numerical data
Surveys and Questionnaires
Cost of illness
Health expenditures
Health surveys
Neoplasms
Psychological
Rural health
Stress
Survivors
Journal
Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
17
07
2019
revised:
19
10
2019
accepted:
30
10
2019
pubmed:
16
11
2019
medline:
26
8
2020
entrez:
16
11
2019
Statut:
ppublish
Résumé
Some cancer survivors report spending 20% of their annual income on medical care. Undue financial burden that patients face related to the cost of care is referred to as financial hardship, which may be more prevalent among rural cancer survivors. This study examined contrasts in financial hardship among 1419 rural and urban cancer survivors using the 2011 Medical Expenditure Panel Survey supplement - The Effects of Cancer and Its Treatment on Finances. We combined four questions, creating a measure of material financial hardship, and examined one question on financial worry. We conducted multivariable logistic regression analyses, which produced odds ratios (OR) for factors associated with financial hardship and worry, and then generated average adjusted predicted probabilities. We focused on rural and urban differences classified by metropolitan statistical area (MSA) designation, controlling for age, education, race, marital status, health insurance, family income, and time since last cancer treatment. More rural cancer survivors reported financial hardship than urban survivors (23.9% versus 17.1%). However, our adjusted models revealed no significant impact of survivors' MSA designation on financial hardship or worry. Average adjusted predicted probabilities of financial hardship were 18.6% for urban survivors (Confidence Interval [CI]: 11.9%-27.5%) and 24.2% for rural survivors (CI: 15.0%-36.2%). For financial worry, average adjusted predicted probabilities were 19.9% for urban survivors (CI: 12.0%-31.0%) and 18.8% for rural survivors (CI: 12.1%-28.0%). Improving patient-provider communication through decision aids and/or patient navigators may be helpful to reduce financial hardship and worry regardless of rural-urban status.
Identifiants
pubmed: 31727380
pii: S0091-7435(19)30357-3
doi: 10.1016/j.ypmed.2019.105881
pmc: PMC7190004
mid: NIHMS1570363
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105881Subventions
Organisme : NCCDPHP CDC HHS
ID : U48 DP005006
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP005017
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP005000
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA211971
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U48 DP005014
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier Inc.
Références
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2006-14
pubmed: 21980008
Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1275-1282
pubmed: 29593011
Cancer. 2015 Apr 15;121(8):1257-64
pubmed: 25564986
Med Care. 2018 Mar;56(3):220-227
pubmed: 29438192
J Oncol Pract. 2012 Jul;8(4):e50-8
pubmed: 23180999
Support Care Cancer. 2019 Dec;27(12):4779-4786
pubmed: 30972645
MMWR Morb Mortal Wkly Rep. 2019 Jun 07;68(22):494-499
pubmed: 31170127
Health Aff (Millwood). 2016 Jan;35(1):54-61
pubmed: 26733701
J Am Coll Surg. 2019 Apr;228(4):342-353.e1
pubmed: 30802505
Clin Gastroenterol Hepatol. 2009 Nov;7(11):1217-23; quiz 1143
pubmed: 19631284
Oncology (Williston Park). 2015 Sep;29(9):633-40
pubmed: 26384798
Cancer. 2013 Oct 15;119(20):3710-7
pubmed: 23907958
Am J Prev Med. 2018 May;54(5):688-698
pubmed: 29550163
Am J Public Health. 2015 Jul;105 Suppl 3:S371-3
pubmed: 25905825
J Natl Cancer Inst. 2011 Jan 19;103(2):117-28
pubmed: 21228314
Breast Cancer Res Treat. 2019 Jan;173(1):31-36
pubmed: 30259283
Cancer. 2019 May 15;125(10):1737-1747
pubmed: 30663039
Cancer. 2008 Feb 15;112(4):909-18
pubmed: 18189295
J Clin Oncol. 2016 Jan 20;34(3):259-67
pubmed: 26644532
JAMA Intern Med. 2015 Jul;175(7):1213-21
pubmed: 25985438
J Cancer Educ. 2017 Mar;32(1):112-118
pubmed: 26362872
J Cancer Educ. 2017 Sep;32(3):460-466
pubmed: 26627904
Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1389-1397
pubmed: 30429132
Am J Med. 2018 Oct;131(10):1187-1199.e5
pubmed: 29906429
J Clin Oncol. 2018 Jun 10;36(17):1695-1701
pubmed: 29668368
J Natl Cancer Inst. 2020 Jun 1;112(6):647-650
pubmed: 31599949
Cancer. 2010 Jul 15;116(14):3493-504
pubmed: 20549763
J Oncol Pract. 2018 Jul;14(7):e412-e420
pubmed: 29906211
Am J Manag Care. 2015 Sep;21(9):607-15
pubmed: 26618364
Cancer. 2018 Sep 15;124(18):3668-3676
pubmed: 30033631
J Oncol Pract. 2015 May;11(3):171-3
pubmed: 25829522